Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) remain as one
of the most global problematic metabolic diseases with rapidly increasing prevalence and …

Brown adipose tissue (BAT) displays the unique capacity to generate heat through
uncoupled oxidative phosphorylation that makes it a very attractive therapeutic target for …

Atypical antipsychotics (AAPs) are commonly prescribed medications to treat schizophrenia,
bipolar disorders and other psychotic disorders. However, they might cause metabolic …

The obesity pandemic is accompanied by increased risk of developing metabolic syndrome
(MetS) and related conditions: non-alcoholic fatty liver disease (NAFLD)/non-alcoholic …

In the last few decades, glucagon-like peptide-1 receptor (GLP-1R) agonists have changed
current guidelines and improved outcomes for individuals with type 2 diabetes. However, the …

Many studies have revealed that circulating long noncoding RNAs (lncRNAs) regulate gene
and protein expression in the process of hepatic fibrosis. Liver fibrosis is a reversible wound …

Nonalcoholic fatty liver disease (NAFLD) affects approximately 25% of the adult population
worldwide. This pathology can progress into end-stage liver disease with life-threatening …

The principle pathological drivers of metabolic dysfunction associated steatohepatitis
(MASH) are obesity and associated insulin resistance, rendering them key therapeutic …

В настоящем издании проанализированы и систематизированы сведения по
клиническому применению лекарственных средств, для которых гепатотропное …

The prevalence of obesity continues to grow rapidly worldwide, posing many public health
challenges of the 21st century. Obese subjects are at major risk for serious diet-related …